Wuhan insulin price negotiation opened, and representatives of pharmaceutical companies wept on the spot

[industry trends of pharmaceutical network] on January 9, Wuhan took the lead in launching negotiation on purchasing insulin with quantity According to the on-site video from the media, the negotiation started from "soul bargaining": "what's the zero point reduction? Is it a reduction?" "We are negotiating on behalf of the National Bureau", "remind you to think again" According to Wuhan insulin "bargaining negotiation" or "notice" causing market shock, the range of insulin drugs with bargaining volume is human insulin and insulin like drugs that are online in "Hubei Province pharmacy centralized purchase service platform" and have trading volume in medical institutions in Wuhan area before June 30, 2019 It is reported that the price negotiation in Wuhan involves more than 1.7 million pieces of insulin The scale and mode of the negotiation are the first in the industry, so it has also been widely concerned by the industry The negotiation involves nine enterprises, including Novo Nordisk, Lilly Suzhou pharmaceutical, Tonghua Dongbao pharmaceutical, UL, Yuheng pharmaceutical, Sanofi (Beijing) pharmaceutical and Ganli pharmaceutical, and will be divided into seven groups for negotiation From the information revealed before, at the beginning, the decline of enterprises obviously did not cooperate with Wuhan, and after some negotiations, there were enterprise representatives crying on the spot This scene is a bit similar, clearly similar to the healthcare negotiation style launched by the national health insurance administration in November 2019 In fact, the detailed rules for the negotiation of insulin carrying capacity have been better than the market expectation, which is different from the strict grouping and negotiation rules previously announced for the chemical products First of all, the original suppliers can continue to win the bid, not each group of single bidder Secondly, there is no requirement for rigid price reduction, and the requirement for guiding price reduction is moderate In addition, according to the calculation of Wuhan's reported volume, the consumption of insulin in Wuhan is about 17 million pieces, the market scale is about 130 million yuan, and the share is small or limited Therefore, it is expected that the price reduction of most insulin products will be better than the market expectation However, industry analysis also shows that in the future, under the national level's attention to "two diseases" (diabetes, hypertension) drug use, the success of Wuhan's above-mentioned model may cause chain effect, causing the whole insulin market shock In addition, the author also learned that on January 8, the results of bid opening for the first batch of drugs in Wuhan, which attracted much attention, had been released Of the 44 generic names (excluding insulin), 39 were successfully purchased Compared with the national low price, the average decrease was 31%, and the single product dropped 93% According to the relevant person in charge of Wuhan Medical Insurance Bureau, according to the actual consumption of Wuhan in 2018, the selected drugs have reached the expectation as a whole, and the price reduction is expected to be 845 million yuan in 2020 In addition, the recently released Wuhan government work report made it clear that in 2020, it will continue to expand the scope and varieties of centralized drug procurement, and effectively reduce the burden of medical treatment for the masses In addition, the head of Wuhan Medical Insurance Bureau said that in the future, nearly 1000 kinds of drugs should be fully adopted On the whole, this Wuhan volume procurement plan has a more complete interpretation on "volume price linkage", and "it is another breakthrough innovation to obtain increment by gradient price reduction" Whether this model will be promoted in the future is not known, but pharmaceutical companies should pay more attention to it.